Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.

被引：0
|
作者：
Ochenduszko, Sebastian
Garcia, Javier
Juan-Fita, Maria Jose
Gonzalez-Barrallo, Ines
Colomina, Julio Herrero
Beveridge, Robert Diaz
Martinez, Silverio Ros
Lafuente, Blanca Sanchez
Tomas, Alberto Jacobo Cunquero
Berrocal, Alfonso
Cerezuela-Fuentes, Pablo
Fra, Pablo Luna
Peeters, Alicia Gervas
Gonzalez, Jose Luis Sanchez
Garcia, Andres Meana
Garcia, Mariasun Algarra
Garcia, Eugenio Palomares
Altozano, Javier Perez
Guerola, Monica Tallon
Maestu, Inmaculada
机构：
[1] Hosp Univ Dr Peset, Valencia, Spain
[2] Hosp Ctr Tourcoing, Tourcoing, France
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Hosp Clin Univ Valencia, INCLIVA, Valencia, Spain
[5] Unidad Canc Gipuzkoa, OSID Onkol, San Sebastian, Spain
[6] Hosp Univ Politecn La Fe, Valencia, Spain
[7] Hosp Clin Univ Virgen Arrixaca, Murcia, Spain
[8] Hosp Gen Univ Valencia, Valencia, Spain
[9] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
[10] Hosp Univ Son Espases, Palma de Mallorca, Spain
[11] Hosp Univ Doctor Peset, Valencia, Spain
[12] Hosp Gen Univ Alicante, Alicante, Spain
[13] Hosp Marina Baixa, Villajoyosa, Spain
[14] Hosp Univ Vinalopo, Elche, Spain
[15] Hosp Virgen Los Lirios, Alcoy, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21529
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting
    Kopecky, Jindrich
    Pasek, Marek
    Lakomy, Radek
    Melichar, Bohuslav
    Mrazova, Ivona
    Kubecek, Ondrej
    Arenbergerova, Monika
    Lemstrova, Radmila
    Svancarova, Alzbeta
    Tretera, Vojtech
    Hlodakova, Alzbeta
    Zvackova, Kamila
    CANCER MEDICINE, 2024, 13 (05):
  • [22] Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients
    Qiu, Lupeng
    Zhao, Xiao
    Shi, Weiwei
    Sun, Shengjie
    Zhang, Guoqing
    Sun, Qiong
    Meng, Jing
    Xiong, Qi
    Qin, Boyu
    Jiao, Shunchang
    MEDICINE, 2020, 99 (24) : E20545
  • [23] Efficacy and safety of anti-programmed death-1 antibody-based combination therapy in advanced or metastatic gastric or gastroesophageal junction cancer in Chinese patients: A real-world study
    Gao, Yifan
    Li, Haoqian
    Qiu, Lei
    Yuan, Hongtu
    Fan, Qing
    Niu, Zuoxing
    Xing, Ligang
    Li, Mingxing
    Yuan, Dandan
    SCIENCE PROGRESS, 2024, 107 (03)
  • [24] Economical simulations for the optimal use of anti-programmed cell death-1 in advanced melanoma patients: Report of a budget impact analysis
    Clarenne, Justine
    Boulanger, Coralie
    Marechal, Antonin
    Visseaux, Laetitia
    Slimano, Florian
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (05) : 1216 - 1219
  • [25] Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
    Valentin, Julie
    Ferte, Thomas
    Dorizy-Vuong, Valerie
    Dousset, Lea
    Prey, Sorilla
    Dutriaux, Caroline
    Pham-Ledard, Anne
    Beylot-Barry, Marie
    Gerard, Emilie
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [26] Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy
    Julian, C.
    Machado, R.
    Girish, S.
    Chanu, P.
    Heinzmann, D.
    Harbron, C.
    Gershon, A.
    Pfeiffer, S.
    Zou, W.
    Quarmby, V.
    Zhang, Q.
    Chen, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S644 - S644
  • [27] Efficacy and safety of anti-PD1 agents in patients with advanced GI malignancies: Real-world data
    Montenegro Luis, S.
    Garcia-Torralba, E.
    Vicente Conesa, M.
    Ricote Sanchez, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S80 - S80
  • [28] Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
    Hamid, Omid
    Chow, Laura Quan Man
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Clinical and histologic assessment of lichenoid/interface dermatitis observed in patients with advanced malignancies on anti-Programmed cell Death-1 (anti-PD-1) therapy with or without ipilimumab
    Chou, S.
    Hwang, S.
    Carlos, G.
    Wakade, D.
    Fernandez-Penas
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 12 - 13
  • [30] A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors
    Desai, Jayesh
    Markman, Ben
    Sandhu, Shahneen Kaur
    Gan, Hui Kong
    Friedlander, Michael
    Tran, Ben
    Meniawy, Tarek
    Boolell, Vishal
    Colyer, Duncan
    Norris, Christie
    Ameratunga, Malaka
    Yang, Jason
    Li, Kang
    Wang, Lai
    Luo, Lusong
    Qin, Zhen
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345